A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Recruiting
Observational Study
Multiple Myeloma
Amyloidosis
Cryoglobulinemia
Castleman's Disease
Light Chain Deposition Disease
Heavy Chain Deposition Disease
Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes
Smoldering Multiple Myeloma
Plasma Cell Leukemia
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Monoclonal Gammopathy of Renal Significance (MGRS)
Monoclonal Gammopathy of Neurological Significance (MGNS)
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 2,000 (estimated)
- Sponsor
- Peking University First Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banke…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Patients included are those with confirmed diagnosis of PCDs and hospitalized into Peking University First Hospital (PKUFH)
2. Patients of plasma cell disorders (PCDs) are recruited. PCDs include monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple my…
Contacts